Abstract: Compounds and methods are described for the differential inhibition of tyrosine phosphorylation of phospholipase C-.gamma.1 for the prevention or reversal of transplant rejection as well as therapy for autoimmune diseases. Methods for the treating or preventing tissue or organ transplant rejection and methods for treating an autoimmune disease comprising the administration of monoclonal antibodies that specifically bind to the CD45RB epitope of the CD45RB isoform are disclosed.
Abstract: The DNA encoding the cell surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant production of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the detection of thrombin and for the evaluation of candidate thrombin agonists and antagonists. Further, the elucidation of the structure of the thrombin receptor permits the design of agonist and antagonist compounds which are useful diagnostically and therapeutically. The availability of the thrombin receptor also permits production of antibodies specifically immunoreactive with the receptor per se or with specific regions thereof which are also useful diagnostically or therapeutically.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
February 15, 2000
Assignees:
The Regents of the University of California, COR Therapeutics, Inc.
Inventors:
Shaun R. Coughlin, Robert M. Scarborough
Abstract: A nucleic acid comprising a base sequence which codes for a CEA family member peptide sequence or nucleic acids having a base sequence hybridizable therewith, replicable recombinant cloning vehicles having an insert comprising such nucleic acid, cells transfected, infected or injected with such cloning vehicles, polypeptides expressed by such cells, synthetic peptides derived from the coding sequence of CEA family member nucleic acids, antibody preparations specific for such polypeptides, immunoassays for detecting CEA family members using such antibody preparations and nucleic acid hybridization methods for detecting CEA family member nucleic acid sequences using a nucleic acid probe comprising the above described nucleic acid.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
February 8, 2000
Assignee:
Bayer Corporation
Inventors:
Thomas R. Barnett, James J. Elting, Michael E. Kamarck, Axel W. Kretschmer
Abstract: A nucleic acid comprising a base sequence which codes for a CEA family member peptide sequence or nucleic acids having a base sequence hybridizable therewith, replicable recombinant cloning vehicles having an insert comprising such nucleic acid, cells transfected, infected or injected with such cloning vehicles, polypeptides expressed by such cells, synthetic peptides derived from the coding sequence of CEA family member nucleic acids, antibody preparations specific for such polypeptides, immunoassays for detecting CEA family members using such antibody preparations and nucleic acid hybridization methods for detecting CEA family member nucleic acid sequences using a nucleic acid probe comprising the above described nucleic acid.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
January 11, 2000
Assignee:
Bayer Corporation
Inventors:
Thomas R. Barnett, James J. Elting, Michael E. Kamarck, Axel W. Kretschmer
Abstract: The invention provides isolated nucleic acids molecules, designated Siva nucleic acid molecules, which encode proteins involved in immune cell apoptosis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing Siva nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a Siva gene has been introduced or disrupted. The invention still further provides isolated Siva proteins, fusion proteins, antigenic peptides and anti-Siva antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
Type:
Grant
Filed:
May 29, 1997
Date of Patent:
January 4, 2000
Assignee:
Dana-Farber Cancer Institute
Inventors:
Prasad V. S. Kanteti, Zhaohui Ao, Stuart F. Schlossman
Abstract: The present invention is particularly directed to the use of a derivative of vinblastine, 3',4'-anhydrovinblastine (AHVB), which differs from vinblastine in that it possesses a double bond at the 3',4' position of the caranthine nucleus rather than the hydroxyl group that is present in the parent structure, as an antineoplastic agent in the therapeutic treatment of cancer. Specifically, the treatment of lymphoma with 3',4'-anhydrovinblastine is disclosed.
Type:
Grant
Filed:
July 26, 1996
Date of Patent:
January 4, 2000
Assignee:
University of British Columbia
Inventors:
Bruce Schmidt, James Kutney, Lawrence Mayer
Abstract: Therapeutic agents and methods for treating and diagnosing leukemia are provided. Such agents comprises monoclonal antibody M195, a polypeptide capable of binding to the antigen of M195, or a chimeric antibody such a peptide, conjugated to a cytotoxic agent, e.g. a radioisotope or alone. Methods for delivering genetic information to a targeted cell is also provided.
Type:
Grant
Filed:
June 15, 1992
Date of Patent:
December 28, 1999
Assignee:
Sloan-Kettering Institute for Cancer Research
Abstract: Aminoterminal propeptide of type I procollagen exists in serum in two forms: classical type I procollagen which is a heterotrimer containing two pro .alpha.1-chains and one pro .alpha.2-chain of type I procollagen, and an .alpha.1-homotrimer type I procollagen containing three identical pro .alpha.1-chains. These intact, trimeric aminoterminal propeptides may be isolated without the use of proteolytic enzymes and the resultant propeptides may be used to prepare antibodies specific for the intact trimeric propeptide, having no affinity for the monomeric form of the propeptide. Such antibodies are useful in methods of assaying intact trimeric aminoterminal propeptide of type I procollagen in serum, without false information resulting from inadvertent assay of the monomeric form of the propeptide.
Type:
Grant
Filed:
March 2, 1998
Date of Patent:
December 28, 1999
Assignee:
Orion Diagnostica
Inventors:
Juha Risteli, Leila Risteli, Jukka Melkko, Saila Kauppila
Abstract: The present invention provides a substantially pure phopholipase A.sub.2 protein isolated and purified from rabbit kidney cortex, having a molecular weight of 28 kDa as determined by SDS-PAGE, is calcium independent, is cytosolic, has a specific activity of approximately 1.2 .mu.mol/mg protein/minute and a pH optimum of approximately 7.5 and exhibits a preferential hydrolysis toward sn-2 fatty acid from diradylglycerophospholipids. Also provided are a first monoclonal antibody that specifically binds to the protein of claim 1 various methods of using, inhibiting or measuring said protein.
Type:
Grant
Filed:
June 8, 1998
Date of Patent:
December 21, 1999
Assignee:
The Board of Trustees of the University of Arkansas
Abstract: The invention relates to macrophages which have at least one of the following properties: their cytotoxic activity without IFN-.gamma. is increased by about 20 to 30% with respect to standard macrophages, and is preferably of about 70%; their cytotoxic activity with IFN-.gamma. is increased by about 20 to about 40% with respect to standard macrophages, and is preferably of about 93%; the extension of the deactivation of the cytotoxic activity in reply to an activation of IFN-.gamma. is in a ratio such that after 60 h of activation with IFN-.gamma., the cytotoxic activity is higher than or equal to 30%, preferably of about 55%, compared to the maximum cytotoxic activity presented by the macrophages due to IFN-.gamma. activation, with said cytotoxic activity being measured as the percentage of inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells.
Abstract: The invention is directed toward a compound comprising a recombinant nucleic acid encoding an immunoadhesin inserted within an adenoviral nucleic acid, wherein the recombinant nucleic acid can be packaged in an adenovirus particle and wherein expression of the recombinant nucleic acid encoding the immunoadhesin results in production of the immunoadhesin protein. The recombinant nucleic acid encoding the immunoadhesin can be within an adenovirus.
Type:
Grant
Filed:
March 10, 1997
Date of Patent:
December 7, 1999
Assignee:
The United States of America, as represented by the Department of Health and Human Services
Inventors:
Karl G. Csaky, Eddy Anglade, Daniel M. Sullivan, William LaRochelle
Abstract: A method for treating neoplastic disease in a mammal via administering to the mammal a therapeutically effective amount of an interferon via oromucosal contact. The amount of interferon administered is less than an amount which induces a pathological response when administered parenterally.
Type:
Grant
Filed:
May 9, 1997
Date of Patent:
December 7, 1999
Assignee:
Pharma Pacific Pty Ltd.
Inventors:
Michael Gerard Tovey, Thomas James Kaido
Abstract: Peptide antigens derived from the carboxy terminus of somatostatin receptors and antibodies produced using the peptide antigens. The anti-somatostatin receptor antibodies are specific for a receptor subtype and are useful in characterizing receptor subtypes expressed by tissues.
Abstract: Materials immunoreactive with parathyroid hormone-related protein (PTH-rp) are used in the invention method to prevent and treat cancer metastasis to bone and cancer cell growth in bone as well as osteolysis and symptomatic sequelae thereof. Antibodies with human characteristics are included in the invention for application of the invention method to human subjects.
Type:
Grant
Filed:
February 9, 1995
Date of Patent:
November 30, 1999
Assignee:
Xenotech
Inventors:
Toshiyuki Yoneda, Gregory R. Mundy, Theresa A. Guise
Abstract: This invention relates to immunological reagents and methods specific for a mammalian, transmembrane protein termed Pgp, having a non-specific efflux pump activity established in the art as being a component of clinically-important multidrug resistance in cancer patients undergoing chemotherapy. The invention provides methods for developing and using immunological reagents specific for certain mutant forms of Pgp and for wild-type Pgp in a conformation associated with substrate binding or in the presence of ATP depleting agents. The invention also provides improved methods for purifying hematopoietic stems cells expressing Pgp and diagnostic and therapeutic methods for cancer cells expressing Pgp.
Type:
Grant
Filed:
November 15, 1996
Date of Patent:
November 30, 1999
Assignee:
Board of Trustees of the University of Illinois
Abstract: A method for inducing or enhancing in a human subject the production of antibodies reactive with the polypeptide subunit of Urinary Tumor Associated Antigen having a molecular weight of about 90 to 100 kD after reduction by .beta.-mercaptoethanol and separation by SDS-polyacrylamide gel electrophoresis is disclosed. The method comprises administering to the subject an effective dose of a composition comprising inactivated tumor cells having Urinary Tumor Associated Antigen on the cell surface and at least one tumor associated antigen selected from the group consisting of GM-2, GD-2, Fetal Antigen and Melanoma Associated Antigen.
Abstract: Recombinant, in particular humanised, e.g. humanised chimeric and CDR-grafted humanised, antibody molecules having specificity for human TNF.alpha., are provided for use in diagnosis and therapy. In particular, the antibody molecules have antigen binding sites derived from murine monoclonal antibodies CB0006, CB0010, hTNF3 or 101.4. Preferred CDR-grafted humanised anti-hTNF.alpha. antibodies comprise variable region domains comprising human acceptor framework and donor antigen binding regions and wherein the frameworks comprise donor residues at specific positions. The antibody molecules may be used for therapeutic treatment of human patients suffering from or at risk of disorders associated with undesirably high levels of TNF, in particular for treatment of immunoregulatory and inflammatory disorders or of septic, endotoxic or cardiovascular shock.
Type:
Grant
Filed:
June 1, 1995
Date of Patent:
November 30, 1999
Assignee:
Celltech Therapeutics Limited
Inventors:
John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage, Mark William Bodmer
Abstract: Natural suppressor (NS) cells secrete a soluble protein suppressor factor (SF) which suppresses the mixed lymphocyte response. NS cells as described herein are null, i.e., have the phenotype IL-2R.sup.+, CD3.sup.-, CD4.sup.-, CD8.sup.-, TCR.alpha..beta..sup.-, Ig.sup.-, MAC-1.sup.-, or are double negative suppressors (DNS); i.e., have the phenotype IL-2R.sup.+, CD3.sup.+, CD4.sup.-, CD8.sup.-, TCR.alpha..beta..sup.+. Both NS and SF are useful in vivo to confer immunotolerance with respect to allogeneic transplants, and to effect immunosuppression. They also enhance engraftment of transplanted cells. A population of cells can be provided using density gradient separation techniques which is enriched in progenitor cells as identified by the presence of CD34 surface markers.
Type:
Grant
Filed:
November 4, 1992
Date of Patent:
November 16, 1999
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: The present invention discloses a procedure for the destruction of contaminating tumor cells in stem cell transplants ex vivo using intact bispecific antibodies.
Type:
Grant
Filed:
September 3, 1997
Date of Patent:
November 16, 1999
Assignee:
GSF Forschungszentrum fur Umwelt und Gesundheit GmbH
Inventors:
Horst Lindhofer, Helge Menzel, Hans-Jochem Kolb, Stefan Thierfelder
Abstract: The invention relates to monoclonal antibodies to human leukemia inhibitory factor. The disclosed monoclonal antibodies are believed to recognize unique epitopes on hLIF and are useful in the treatment of conditions wherein the presence of hLIF causes or contributes to undesirable pathological effects, such as cachexia, dysregulated calcium metabolism, or excessive bone cell proliferation, and in the detection of hLIF, for example, in clinical samples or specimens.